Gentamicin induces sub-therapeutic levels of coagulation factor VII in patients with nonsense mutations [1]

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 8, 2006, Pages 1828-1830

  Pinotti, Mirko ^a   Rizzotto, L ^a   Chuansumrit, A ^b   Mariani, G ^c   Bernardi, F ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; GENTAMICIN; MESSENGER RNA; RECOMBINANT BLOOD CLOTTING FACTOR 7; RECOMBINANT PROTEIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLOOD SAMPLING; CASE REPORT; CLINICAL PROTOCOL; DOSE RESPONSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROGRAPHY; HOMOZYGOSITY; HUMAN; IN VIVO STUDY; LETTER; LEUKOCYTE; MUTATIONAL ANALYSIS; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTHROMBIN TIME; SENSITIVITY ANALYSIS; STOP CODON; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CODON, NONSENSE; FACTOR VII; FACTOR VII DEFICIENCY; GENTAMICINS; HOMOZYGOTE; HUMANS; KINETICS; LEUKOCYTES; MUTATION; PROTHROMBIN TIME; TIME FACTORS;

EID: 33746611902     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02057.x     Document Type: Letter

References (18)

1. Rapaport SI, Rao RVM. The tissue factor pathway: How it has become a 'prima ballerina'. Thromb Haemost 1995; 74: 7-17.
2. Rosen ED, Chan JC, Idusogie E, Clotman F, Vlasuk G, Luther T, Jalbert LR, Albrecht S, Zhong L, Lissens A, Schoonjans L, Moons L, Collen D, Castellino FJ, Carmeliet P. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature 1997; 390: 290-4.
3. Mariani G, Herrmann FH, Dolce A, Batorova A, Etro D, Peyvandi F, Wulff K, Schved JF, Auerswald G, Ingerslev J, Bernardi F; International Factor VII Deficiency Study Group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005; 93: 481-7.
4. McVey JH, Boswell E, Mumford AD, Kemball-Cook G, Tuddenham EG. Factor VII deficiency and the FVII mutation database. Hum Mutat 2001; 17: 3-17.
5. Pinotti M, Rizzotto L, Pinton P, Ferraresi P, Chuansumrit A, Charoenkwan P, Marchetti G, Rizzuto R, Mariani G, Bernardi F, for the International Factor VII Deficiency Study Group. Intracellular readthrough of nonsense mutations by aminoglycosides in coagulation factor VII. J Thromb Haemost 2006; 4: 1308-14.
6. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996; 2: 467-9.
7. Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, Tousson A, Clancy JP, Sorscher EJ. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997; 3: 1280-4.
8. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999; 104: 375-81.
9. Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet 2001; 10: 291-9.
10. Sangkuhl K, Schulz A, Rompler H, Yun J, Wess J, Schoneberg T. Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo. Hum Mol Genet 2004; 13: 893-903.
11. Lai CH, Chun HH, Nahas SA, Mitui M, Gamo KM, Du L, Gatti RA. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci USA 2004; 101: 15676-81.
12. Wilschanski M, Yahav H, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, Kerem B, Kerem E. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349: 1433-41.
13. James PD, Raut S, Rivard GE, Poon MC, Warner M, McKenna S, Leggo J, Lillicrap D. Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood 2005; 106: 3043-8.
14. Byers PH. Killing the messenger: New insights into nonsense-mediated mRNA decay. J Clin Invest 2002; 109: 3-6.
15. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicine in patients with serious infections. Lancet 1993; 341: 335-9.
16. Pinotti M, Etro D, Bindini D, Papa ML, Rodorigo G, Rocino A, Mariani G, Ciavarella N, Bernardi F. Residual factor VII activity and different hemorrhagic phenotypes in CRM(+) factor VII deficiencies (Gly331Ser and Gly283Ser). Blood 2002; 99: 1495-7.
17. Broze Jr GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-12.
18. Furlan Freguia C, Toso R, Pollak ES, Arruda VR, Pinotti M, Bernardi F. Characterization of mild coagulation factor VII deficiency: Activity and clearance of the Arg315Trp and Arg315Lys variants in the Cys310-Cys329 loop (c170s). Haematologica 2004; 89: 1504-9.